Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here.
Announcing the launch of Mini Reviews
New Thematic Series - AI in Dementia
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here.
Articles
-
-
The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
-
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
-
Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
-
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Alzheimer's blogs from BMC
-
-
World Alzheimer’s Month: Let’s talk about dementia to end the stigma
20 September 2019
-
Spotlight on Alzheimer’s Research: Brain Awareness Week 2019
27 February 2019
Affiliated with
Annual Journal Metrics
-
Speed
58 days to first decision for reviewed manuscripts only
39 days to first decision for all manuscripts
130 days from submission to acceptance
18 days from acceptance to publication
Citation Impact
6.116 - 2-year Impact Factor
7.114 - 5-year Impact Factor
1.546 - Source Normalized Impact per Paper (SNIP)
2.298 - SCImago Journal Rank (SJR)
Usage
825,177 downloads
1,767 Altmetric mentions